Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

Background:  Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered‐dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide pMDI and budesonide/formoterol dry‐powder inhaler (DPI; Turbuhaler®).

[1]  J. Oppenheimer.  Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines , 2006 .

[2]  P-C. Yang,et al.  Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. , 2006, Pulmonary pharmacology & therapeutics.

[3]  H. Zwick,et al.  Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. , 2006, Respiratory medicine.

[4]  K. Rabe,et al.  Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. , 2006, Chest.

[5]  L. Borgström,et al.  Performance of Turbuhaler((R)) in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma : Understanding the Clinical Importance of Adequate Peak Inspiratory Flow, High Lung Deposition, and Low In Vivo Dose Variability. , 2006, Treatments in respiratory medicine.

[6]  D. Price,et al.  Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? , 2005, European Respiratory Journal.

[7]  B. Rubin,et al.  Problems with inhaler use: a call for improved clinician and patient education. , 2005, Respiratory care.

[8]  C. Leach.  The CFC to HFA transition and its impact on pulmonary drug development. , 2005, Respiratory care.

[9]  H. Bisgaard,et al.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. , 2005, American journal of respiratory and critical care medicine.

[10]  J. L. Rau,et al.  Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. , 2005, Chest.

[11]  L. Boulet,et al.  Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma , 2004, Current medical research and opinion.

[12]  V. Backer,et al.  Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma , 2004, Current medical research and opinion.

[13]  T. Ekström,et al.  BUDESONIDE/FORMOTEROL ADJUSTABLE MAINTENANCE DOSING REDUCES ASTHMA EXACERBATIONS VERSUS FIXED DOSING , 2003, International journal of clinical practice.

[14]  I. Naya,et al.  Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. , 2003, Respiratory medicine.

[15]  E. Bateman,et al.  Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[16]  L. Boulet,et al.  Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. , 2003, Canadian respiratory journal.

[17]  K. De Boeck,et al.  Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma , 2002, Pediatric pulmonology.

[18]  C. Löfdahl,et al.  Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. , 2001, British journal of clinical pharmacology.

[19]  O. Zetterström,et al.  Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. , 2001, The European respiratory journal.

[20]  E. Bateman,et al.  Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. , 2001, Respiratory medicine.

[21]  A. Miller-Larsson,et al.  Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. , 2000, American journal of respiratory and critical care medicine.

[22]  A. Andersson,et al.  Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. , 2000, Respiratory medicine.

[23]  A. Foresi,et al.  Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. , 2000, Chest.

[24]  J. Lötvall,et al.  Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. , 1999, American journal of respiratory and critical care medicine.

[25]  A. Buist,et al.  Validation of a standardized version of the Asthma Quality of Life Questionnaire. , 1999, Chest.

[26]  D. Bristol.  Clinical equivalence. , 1999, Journal of biopharmaceutical statistics.

[27]  B. Gabrio,et al.  Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[28]  M. Dahlbäck,et al.  Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[29]  T L Petty,et al.  Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. , 1998, The Journal of allergy and clinical immunology.

[30]  J. Lötvall,et al.  Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. , 1997, The European respiratory journal.

[31]  Эльна Берг,et al.  The inhalation device , 1996 .

[32]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[33]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[34]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[35]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[36]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[37]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[38]  Mark J FitzGerald,et al.  Acute Asthma , 1986, The Lancet.

[39]  V. Guess.  Pulmonary Function Testing in Children: Techniques and Standards , 1972 .